How Do Dezawa Muse Cells Work? Mechanism of Action

How do Dezawa Muse cells work in the body?

The biology of Dezawa Muse cells is built around a sequence of molecular events that distinguish them from conventional stem cell populations. Where most mesenchymal stem cells (MSCs) administered by IV infusion become trapped in pulmonary capillaries before they can reach damaged tissue, published research suggests Muse cells have a specific navigation system, a differentiation trigger, and a survival architecture that allow them to operate inside the harsh conditions of an injury site.

Understanding how these mechanisms work requires stepping through each one individually. The research base for these mechanisms spans laboratory studies, preclinical animal models, and early human clinical programs. It is important to note throughout this article that the mechanistic science is better established than the clinical efficacy data. Preliminary research indicates these pathways are real and active; what remains limited is large-scale controlled evidence of clinical outcomes in humans.

What is the S1P-S1PR2 homing system?

The most studied mechanism of Muse cell behavior is their homing to injury sites via the sphingosine-1-phosphate (S1P) and S1P receptor 2 (S1PR2) signaling axis.

When tissue is damaged or cells are dying, they release sphingosine-1-phosphate into the surrounding environment. Sphingosine-1-phosphate is a bioactive lipid molecule that functions as a distress signal - it is not specific to any one tissue type, which means damaged heart, brain, kidney, or other tissue all produce it. Muse cells express S1PR2 at substantially higher levels than non-Muse MSCs, giving them the molecular machinery to detect and respond to this signal.

A 2018 study published in Circulation Research (Yamada et al., DOI: 10.1161/CIRCRESAHA.117.311648) provided direct experimental confirmation of this mechanism in a cardiac injury model. The researchers demonstrated that:

• Approximately 14.5 percent of injected Muse cells engrafted into damaged heart tissue within three days.
• Blocking S1PR2 with the specific antagonist JTE-013 eliminated the homing behavior entirely.
• Silencing S1PR2 expression via RNA interference (siRNA) produced the same result - confirming the pathway, not just the pharmacological block.
• Engraftment supported functional recovery sustained at six months without immunosuppressants.

In practical terms, this means Muse cells carry a receptor that reads an injury signal present in virtually all forms of tissue damage. The implication for IV delivery is meaningful: rather than dispersing randomly or getting filtered in the lungs, published data suggests Muse cells can preferentially traffic toward the specific site producing S1P.

How do Muse cells differentiate spontaneously?

Once Muse cells arrive at an injury site, the differentiation trigger is not an injected cytokine or a laboratory protocol. According to published research, it is phagocytosis - the same cellular process macrophages use to engulf and clear debris, repurposed here for tissue repair.

The phagocytosis-differentiation mechanism

At an injury site, cells are in various stages of apoptosis (programmed death). Muse cells engulf fragments of these dying cells using a distinct set of phagocytic receptors. A 2022 study in Cellular and Molecular Life Sciences (Wakao et al., DOI: 10.1007/s00018-022-04555-0) identified the primary receptors involved: ITGB3, CD91/LRP-1, RAGE, and CD36 - with CD36 and ITGB3 upregulated approximately 4.5-fold. These differ from the receptor subsets macrophages use, which is significant for understanding what happens next.

When a macrophage engulfs a dying cell, it digests the contents completely as part of immune cleanup. Muse cells do not. The engulfed cell fragments are processed differently: transcription factors from the apoptotic cell are released into the Muse cell cytoplasm, translocate into the nucleus, and bind to promoter regions of the Muse cell genome. The result is rapid lineage-specific gene expression.

The Wakao et al. study demonstrated this using cardiomyocytes as the engulfed cell type. GATA-4, a transcription factor from apoptotic cardiomyocytes, was transferred into the Muse cell nucleus, recruited RNA polymerase II, and drove expression of cardiac lineage markers. The timeline was striking: lineage-specific markers appeared within 24 to 36 hours of phagocytosis. By comparison, cytokine-driven differentiation protocols in cell culture typically require several weeks.

This mechanism creates what researchers have described as a contextual differentiation system: the tissue environment itself tells the Muse cell what to become, rather than requiring an external instruction in the form of a growth factor cocktail.

Specificity of differentiation

A critical aspect of this mechanism is that differentiation follows the identity of what was engulfed. When Muse cells phagocytose fragments of neural cells, they express neural lineage markers. When they engulf cardiomyocytes, they express cardiac markers. This tissue-matched response distinguishes Muse cell phagocytosis from the behavior of macrophages, which digest everything they engulf without a differentiation outcome.

Why don't Muse cells require immunosuppressants?

One of the practical questions about any allogeneic (donor-derived) cell therapy is immune rejection. If cells from another person are infused, the recipient's immune system will typically recognize them as foreign and mount an attack - which is why organ transplant recipients take immunosuppressive drugs indefinitely. Published data on Muse cells suggests they evade this response through a multi-layered immune privilege profile.

HLA-G expression

Muse cells express HLA-G, a non-classical human leukocyte antigen molecule. Classical HLA molecules present cellular contents to T cells for recognition as self or foreign. HLA-G functions differently: it sends inhibitory signals to natural killer (NK) cells and T cells, telling them not to attack. It is expressed naturally in the placenta, where it protects the fetus (genetically foreign to the mother) from maternal immune attack. Published research has reported Muse cells expressing HLA-G at 5-7 times higher levels than standard MSCs.

IDO and TGF-beta1

IDO (indoleamine 2,3-dioxygenase) is an enzyme that depletes local tryptophan - an amino acid T cells require to proliferate. By consuming tryptophan in the local environment, Muse cells create conditions unfavorable for T cell activation. Published proteomic analysis also identifies TGF-beta1 in the Muse cell secretome at approximately 3.2-fold higher levels than non-Muse MSCs, providing additional anti-inflammatory signaling.

Absence of HLA-DR

Muse cells lack HLA-DR, the classical MHC class II molecule that antigen-presenting cells use to activate helper T cells. Without HLA-DR expression, Muse cells are less visible to the adaptive immune system's recognition machinery.

This combination - HLA-G positive, IDO positive, TGF-beta1 elevated, HLA-DR negative - creates what researchers describe as an immune privilege profile. A 2024 study published in Communications Medicine demonstrated structural reconstruction in a mouse aortic dissection model using intravenously administered human Muse cells without immunosuppression (Nature Publishing Group, DOI: 10.1038/s43856-024-00597-6). Clinical trial programs in Japan have similarly administered Muse cells to human patients without immunosuppressive protocols, with no reported serious immune-related adverse events to date.

It is worth noting that "no immunosuppressants required in early trials" does not mean immune rejection is impossible in all patients or settings. This remains an active area of research.

How do Muse cells survive in damaged tissue?

Injured tissue is biochemically hostile. Hypoxia (low oxygen), oxidative stress, inflammation, and the accumulation of toxic metabolic byproducts are all present at injury sites - the same conditions that cause most injected cell therapies to fail before they can exert any effect. The "Stress-Enduring" part of the Muse cell name reflects a survival biology that was used to discover them in the first place.

How the stress-enduring property was discovered

In the original isolation protocol developed by Professor Mari Dezawa at Tohoku University, mesenchymal stem cell cultures were subjected to extreme stress conditions: prolonged collagenase exposure, serum deprivation, low temperature, and hypoxia. Most cells died. The small population that survived were the cells that became known as Muse cells. The isolation method itself used stress as a purification step - selecting for the cells with the greatest inherent resistance.

Molecular stress-response mechanisms

A comparative proteome analysis of Muse versus non-Muse cells (published in PLOS One and further characterized in PMC7922977) identified several enriched pathways in Muse cells:

• Enhanced reactive oxygen species (ROS) scavenging - greater enzymatic capacity to neutralize oxidative stress.
• Elevated DNA repair machinery - higher expression of proteins involved in repairing damage to the genome under genotoxic stress.
• Endosomal-vacuolar trafficking pathways - linked to managing cellular waste and stress-induced damage to organelles.
• Ubiquitin-proteasome degradation capacity - enhanced ability to clear damaged proteins before they accumulate to toxic levels.

A 2025 study in Scientific Reports (PMC12378945) added another layer: hypoxia actually increases the proportion of Muse cells within an MSC population, driven by HIF2-alpha signaling rather than the more commonly studied HIF1-alpha. The same hypoxia that kills surrounding cells appears to selectively enrich Muse cell survival and, importantly, upregulates let-7 expression, which further reinforces pluripotency gene regulation and non-tumorigenicity under stress.

In practical terms, the tissue environment most hostile to other cell therapies may be the environment where Muse cells are best equipped to function.

What gives Muse cells their pluripotent capacity?

Muse cells are pluripotent, meaning they can give rise to cells from all three embryonic germ layers: ectoderm (skin, nervous system), mesoderm (muscle, bone, heart, blood vessels), and endoderm (organ tissue, digestive system). The question is how they maintain this broad differentiation capacity while residing in adult tissue, and why they do not form tumors the way embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) do in preclinical models.

Pluripotency markers at moderate expression

Muse cells express the canonical pluripotency transcription factors: Nanog, Oct3/4, Sox2, and surface marker SSEA-3. Their expression levels are lower than in ESCs and iPSCs - not absent, but tuned to a stable, moderate level. This appears to reflect a regulated rather than fully activated pluripotent state, which may contribute to the behavioral differences observed in preclinical safety studies.

The Let-7 / Lin28 axis

A 2023 study in Cellular and Molecular Life Sciences (DOI: 10.1007/s00018-023-05089-9) clarified the molecular mechanism underlying Muse cell non-tumorigenicity. In ESCs and iPSCs, Lin28 is highly expressed. Lin28 suppresses the microRNA let-7, which in turn allows the PI3K-AKT signaling pathway to operate at high activity - driving proliferation, glycolysis, and ultimately tumor risk.

Muse cells do not express Lin28. Instead, let-7 is expressed at high levels, which inhibits PI3K-AKT signaling. This has two consequences: pluripotency genes (KLF4, POU5F1, SOX2, Nanog) remain expressed through a let-7-dependent mechanism that does not require Lin28, and cell proliferation is suppressed rather than amplified. The result is cells that maintain pluripotency gene expression without the oncogenic signaling that drives tumor formation in other pluripotent cell types.

Published preclinical safety studies, including long-term implantation in immunodeficient mouse models, have not observed teratoma formation with Muse cells. This safety record - while encouraging - is based on animal models and limited human data, and does not constitute a guarantee of safety in all clinical contexts.

How are Muse cells delivered into the body?

In the clinical trial programs conducted in Japan by Life Science Institute (LSI, a subsidiary of Mitsubishi Chemical Group), the primary delivery route has been intravenous (IV) infusion. The theoretical basis for IV delivery is the S1P-S1PR2 homing mechanism: cells enter circulation, detect sphingosine-1-phosphate gradients from injured tissue, and migrate accordingly.

This is an important practical advantage over therapies requiring local injection or surgical delivery. However, IV administration also means cells pass through the lungs in circulation, and the degree to which the homing mechanism overcomes pulmonary first-pass trapping in humans - across different patients, conditions, and dosing levels - remains an active research question.

Additional delivery routes under preclinical and early clinical investigation include:

• Intranasal delivery - studied for neurological conditions (published in Scientific Reports, 2025; DOI: 10.1038/s41598-025-96451-3), leveraging the olfactory pathway as a route to the central nervous system.
• Intrathecal administration - direct delivery to cerebrospinal fluid for spinal cord and neurological applications.
• Local injection - under investigation for orthopedic applications.

The cells used in published clinical programs are allogeneic - derived from donor tissue (typically umbilical cord), manufactured under controlled conditions, and characterized by SSEA-3 expression as the quality standard. Authentication of the cell product is a meaningful consideration because SSEA-3+ verification is what defines a Muse cell population versus a generic MSC product.

What happens to Muse cells after they reach injured tissue?

The post-homing sequence, based on published research, follows a logical progression:

1. Migration. Muse cells follow S1P gradients from circulation to the injury site, where S1P concentration is highest.
2. Phagocytosis. At the site, Muse cells engulf apoptotic cells using ITGB3, CD91/LRP-1, RAGE, and CD36 receptors. This distinguishes them from macrophages, which phagocytose for clearance rather than differentiation.
3. Transcription factor transfer. Contents from engulfed cells - including lineage-specific transcription factors - are released into the Muse cell cytoplasm and translocate to the nucleus.
4. Rapid differentiation. Within 24 to 36 hours, the Muse cell expresses markers specific to the engulfed cell type, beginning the process of replacing lost tissue.
5. Paracrine support. Throughout this process, Muse cells secrete factors including EGF (epidermal growth factor), PDGF-bb (platelet-derived growth factor), NGF-beta (nerve growth factor), bFGF (basic fibroblast growth factor), and TGF-beta that may support tissue repair in the surrounding environment. These paracrine effects are amplified under hypoxic conditions.
6. Immune persistence. HLA-G and IDO expression allow the cells to maintain activity without triggering rejection, and published animal studies have shown allogeneic Muse cells surviving in tissue for up to six months without immunosuppression.

What the current literature cannot fully characterize is how efficiently this sequence operates in human clinical settings across different patients, tissue types, conditions, and dosing levels. The mechanistic biology is well-supported at the laboratory level; the translation to predictable clinical outcomes in a broad patient population requires more data than currently exists.

How does this compare to conventional MSC therapy?

Most stem cell therapies currently in widespread use rely on mesenchymal stem cells (MSCs), which have a substantial clinical trial record. The mechanistic comparison is instructive.

MSCs are multipotent - they can become bone, cartilage, fat, and some muscle - but they do not differentiate into ectoderm or endoderm lineages. Their primary therapeutic effects are thought to be paracrine: secreting anti-inflammatory and trophic factors rather than replacing lost tissue directly. A significant limitation of IV MSC delivery is pulmonary first-pass trapping: a large fraction of infused MSCs are caught in lung capillaries before reaching target tissue.

Muse cells, by contrast, are pluripotent with documented homing behavior. The Yamada et al. Circulation Research study reported that engraftment in cardiac tissue with Muse cells was approximately 2.5 times higher than with MSCs in the same model, and functional recovery was approximately 2.1 times higher. These figures come from one preclinical model and should not be generalized broadly, but they illustrate the mechanistic difference the S1P-S1PR2 system creates versus MSCs that lack it.

For a full comparison of Muse cells and conventional stem cell therapies, see Dezawa Muse Cells vs Regular Stem Cells: What's the Difference?